ZYESAMI™ (aviptadil acetate)

DRUG2 trials

Sponsors

APR Applied Pharma Research s.a.

Conditions

ALIARDSAcute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)COVIDDyspneaSARS-CoV 2

Phase 2

Inhaled ZYESAMI™ (Aviptadil Acetate) for the Treatment of Severe COVID-19

TerminatedNCT04360096

APR Applied Pharma Research s.a.Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), ALI, ARDS +3

Start: 2021-02-15End: 2021-12-31Updated: 2023-02-03

Phase 3

Inhaled ZYESAMI (Aviptadil Acetate) for Treatment of Severe COVID-19

WithdrawnNCT05137795

APR Applied Pharma Research s.a.Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), ALI, ARDS +3

Start: 2021-12-15End: 2022-08-15Updated: 2026-05-14

Related Papers

Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial

Trials2022-09-202 citations